The results revealed that LOX mRNA expression was considerably increased in the vast majority of human cancers compared with non-cancer tissues, such as cervical squamous cell carcinoma, endocervical adenocarcinoma, cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, prostate adenocarcinoma, rectal adenocarcinoma, and stomach adenocarcinoma, while it was markedly lower in thyroid carcinoma. Here, LOX is linked to glioblastoma.